Press Releases

Arena Pharmaceuticals to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference

SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will present a corporate update at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Monday, April 4, 2005, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). Jack Lief, President and Chief Executive Officer, will give the presentation, which will be webcast live over the Internet. The conference will be held at The Millennium Broadway Hotel in New York, New York.

To access the live or archived presentation, simply log on to the following link http://www.veracast.com/webcasts/cibcwm/biotech05/31104264.cfm or www.arenapharm.com under the investor relations section. Please connect to either one of the websites several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. The archived presentation will be available for 30 days on both websites.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focusing on the discovery, development and commercialization of drugs in four major therapeutic areas: metabolic, cardiovascular, inflammatory and central nervous system diseases. Arena is developing a broad pipeline of compounds that act on an important class of drug targets called G protein-coupled receptors, or GPCRs, using its proprietary technologies, including CART^™ (Constitutively Activated Receptor Technology) and Melanophore. Arena's most advanced clinical compound, APD356, a selective 5-HT2C serotonin receptor agonist for the treatment of obesity, is in a Phase 2 clinical trial. Arena is also conducting a Phase 1 clinical trial on APD125, a compound with a novel mechanism of action (selective 5-HT2A receptor antagonist), for the treatment of insomnia. Arena has research collaborations with Ortho-McNeil Pharmaceutical, Inc., Merck & Co., Inc., and other companies for products in a number of different indications.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, technologies, preclinical and clinical programs, and ability to develop compounds. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's research, out-licensing endeavors and clinical studies, Arena's ability to obtain additional financing, and the timing and receipt of payments and fees, if any, from Arena's collaborators, including Ortho-McNeil and Merck. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Arena Pharmaceuticals^® and Arena^® are registered service marks of the company. CART^™ is an unregistered service mark of the company.

SOURCE Arena Pharmaceuticals, Inc.
03/29/2005
CONTACT: Jack Lief, President and CEO of Arena Pharmaceuticals, +1-858-453-7200, ext. 223; or Media & Investor Relations, Susan Neath of Atkins + Associates, +1-858-527-3486, for Arena Pharmaceuticals
Web site: http://www.arenapharm.com